Literature DB >> 12716238

How long should patients with psychotic depression stay on the antipsychotic medication?

Anthony J Rothschild1, Suzanne E Duval.   

Abstract

BACKGROUND: Patients who have major depression with psychotic features have greater morbidity and mortality than patients with nonpsychotic major depression. In particular, relapse and recurrence have been reported to occur more frequently in patients with psychotic depression than nonpsychotic depression. Despite the frequent relapse and recurrence in major depression with psychotic features, there are few studies of the efficacy of continuation and maintenance treatments.
METHOD: Forty patients with a diagnosis of unipolar DSM-III-R major depression with psychotic features were treated with fluoxetine and perphenazine for 5 weeks after granting written informed consent. The patients who responded to treatment continued to receive the combination for an additional 3 months. If a patient was stable for 4 months on treatment with the combination, the patient was then gradually tapered off perphenazine treatment. For patients who exhibited impending relapse, perphenazine was restarted. Impending relapse was defined as any of the following: (1) symptoms meeting DSM-IV criteria for major depressive disorder (with or without psychotic features), (2) a total score of > or = 17 on the HAM-D, or (3) the presence of any psychotic symptoms. After 1 year of taking fluoxetine, patients were tapered off fluoxetine treatment. Data were gathered from 1992 to 1997.
RESULTS: Thirty patients responded to the initial 5 weeks of treatment with perphenazine and fluoxetine. After taper of perphenazine following 4 months of treatment with fluoxetine and perphenazine, 22 (73%) of the 30 patients exhibited no signs of relapse over the next 11 months (8 months of fluoxetine monotherapy followed by a taper of fluoxetine and 3 additional months of assessment). Patients who showed signs of relapse after taper of the antipsychotic were more likely to have had a longer duration of the current episode and a history of more frequent past episodes and were more likely to be younger (under the age of 30 years).
CONCLUSION: The data from this study suggest that a majority of patients who have major depression with psychotic features do not require treatment with antipsychotic medication for more than 4 months.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12716238     DOI: 10.4088/jcp.v64n0405

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.

Authors:  Alastair J Flint; Barnett S Meyers; Anthony J Rothschild; Ellen M Whyte; George S Alexopoulos; Matthew V Rudorfer; Patricia Marino; Samprit Banerjee; Cristina D Pollari; Yiyuan Wu; Aristotle N Voineskos; Benoit H Mulsant
Journal:  JAMA       Date:  2019-08-20       Impact factor: 56.272

3.  Acceptance-based Behavior Therapy for Depression With Psychosis: Results From a Pilot Feasibility Randomized Controlled Trial.

Authors:  Brandon A Gaudiano; Andrew M Busch; Susan J Wenze; Kathryn Nowlan; Gary Epstein-Lubow; Ivan W Miller
Journal:  J Psychiatr Pract       Date:  2015-09       Impact factor: 1.325

4.  An open trial of a new acceptance-based behavioral treatment for major depression with psychotic features.

Authors:  Brandon A Gaudiano; Kathryn Nowlan; Lily A Brown; Gary Epstein-Lubow; Ivan W Miller
Journal:  Behav Modif       Date:  2012-12-06

Review 5.  Challenges in the treatment of major depressive disorder with psychotic features.

Authors:  Anthony J Rothschild
Journal:  Schizophr Bull       Date:  2013-04-18       Impact factor: 9.306

6.  The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.

Authors:  Daniel M Blumberger; Benoit H Mulsant; Dora Kanellopoulos; Ellen M Whyte; Anthony J Rothschild; Alastair J Flint; Barnett S Meyers
Journal:  J Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.153

7.  Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.

Authors:  Charles B Nemeroff; Christine M Heim; Michael E Thase; Daniel N Klein; A John Rush; Alan F Schatzberg; Philip T Ninan; James P McCullough; Paul M Weiss; David L Dunner; Barbara O Rothbaum; Susan Kornstein; Gabor Keitner; Martin B Keller
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-13       Impact factor: 11.205

Review 8.  Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment.

Authors:  Arusha Farahani; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2012-04       Impact factor: 4.384

9.  Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II.

Authors:  Alastair J Flint; Barnett S Meyers; Anthony J Rothschild; Ellen M Whyte; Benoit H Mulsant; Matthew V Rudorfer; Patricia Marino
Journal:  BMC Psychiatry       Date:  2013-01-25       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.